RxDoctor Payments DataLook up a doctor →

Elias Kassab, MD

Cardiovascular Disease · Dearborn, MINPI 1922076835

Payments from drug & device makers

$352,230in general payments, 2019–2025

Across 983 payments — averaging $358.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$124K
  • Cardiovascular Systems Inc.$63K
  • Eli Lilly$49K
  • Vesper Medical$33K
  • Trireme Medical LLC$12K
  • E.r. Squibb & Sons, L.L.C.$9K
  • plus $63K from 54 others
$59,091in research payments, 2019–2025

Across 2 payments — averaging $29,546 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$59K

What the payments were for

  • Consulting fees$19,50011%
  • Speaking & faculty fees$22,12513%
  • Grants$110,00064%
  • Travel & lodging$4810%
  • Food & beverage$19,21111%
  • Education$9261%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Catheter Precision, Inc. FKA Ra Medical Systems, Inc.12$123,786
Cardiovascular Systems Inc.62$62,502
Eli Lilly4$49,403
Vesper Medical3$33,208
Trireme Medical LLC2$11,500
E.r. Squibb & Sons, L.L.C.50$9,185
Currax Pharmaceuticals LLC1$8,800
Amgen49$7,623
Bayer11$7,622
Bard Peripheral Vascular, Inc.43$6,745
Boehringer Ingelheim Pharma GmbH & Co.kg1$6,506
Philips North America LLC17$3,753
Boehringer Ingelheim International GmbH1$3,555
Medtronic23$3,186
Johnson & Johnson87$1,363
Angiodynamics, Inc.13$1,192
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)26$1,110
Novo Nordisk58$1,088
Novartis56$838
Merck44$798
AstraZeneca44$782
Tactile Systems Technology Inc31$576
Kowa Pharmaceuticals America, Inc.50$571
Esperion Therapeutics, Inc.34$571
Reflow Medical Inc22$529
Amarin Pharma, Inc.28$443
Abbott14$436
Sanofi-aventis U.S. LLC24$421
Pfizer19$343
Arbor Pharmaceuticals, Inc.14$309
Boehringer Ingelheim18$309
Boston Scientific20$299
Alnylam Pharmaceuticals Inc.10$280
Astellas Pharma US Inc4$277
Ablative Solutions, Inc.3$259
Endologix LLC11$239
Regeneron Healthcare Solutions, Inc.11$226
Kestra Medical Technology Services, Inc.4$165
United Therapeutics Corporation6$164
Getinge USA Sales, LLC3$151
Actelion Pharmaceuticals US, Inc.4$119
Biotronik Inc.1$86
Terumo Medical Corporation4$83
Lexicon Pharmaceuticals, Inc.5$82
Cordis US CORP.4$79
Cardinal Health 200 LLC4$74
Azurity Pharmaceuticals, Inc.4$65
Asahi Intecc USA, Inc.2$64
Bridgebio Pharma, Inc.2$51
Heartflow, Inc.3$49
Recor Medical Inc1$49
Siemens Medical Solutions USA, Inc.2$40
Cardiva Medical, Inc.1$30
Convatec Inc.1$29
Ascendis Pharma Endocrinology Inc1$29
Abiomed1$28
Kiniksa Pharmaceuticals International, PLC1$27
Bardy Diagnostics, Inc.2$25
Vivaquant Inc, Dba Rhythm Express2$23
Z-medica, LLC1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$352,230 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$314,514
Medicare patients
472
Services billed
3,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban276$350,157
EntrestoSacubitril/Valsartan134$176,256
XareltoRivaroxaban139$158,272
JardianceEmpagliflozin132$146,869
Repatha SureclickEvolocumab94$114,170
BrilintaTicagrelor117$91,132
CamzyosMavacamten11$88,857
Praluent PenAlirocumab76$56,367
VerquvoVericiguat19$25,770
NexlizetBempedoic Acid/Ezetimibe20$20,750
FarxigaDapagliflozin Propanediol28$20,683
Repatha SyringeEvolocumab26$19,272
EdarbyclorAzilsartan Med/Chlorthalidone27$14,397
EdarbiAzilsartan Medoxomil21$14,002
Metoprolol Succinate837$13,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$343$350,157276 claims
NovartisEntresto$838$176,256134 claims
Johnson & JohnsonXarelto$1,363$158,272139 claims
Boehringer IngelheimJardiance$309$146,869132 claims
AstraZenecaBrilinta, Farxiga$782$111,814145 claims
E.r. Squibb & Sons, L.L.C.Camzyos$9,185$88,85711 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$309$28,40048 claims
MerckVerquvo$798$25,77019 claims
Esperion Therapeutics, Inc.Nexlizet$571$20,75020 claims
Kowa Pharmaceuticals America, Inc.Livalo$571$8,51913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →